Midostaurin with standard chemotherapy in FLT3 positive Acute Myeloid Leukaemia

Home  /  National Uptake and Case Studies  /  Midostaurin with standard chemotherapy in FLT3 positive Acute Myeloid Leukaemia
CountryAgencyStatusLinkDetails of use
AustriaLBI-HTA2017http://eprints.hta.lbg.ac.at/1140/1/DSD_HSO_Nr.74.pdfNational adaptation, Made no changes to the EUnetHTA report
AustriaGOEGOngoingDissemination to the decision-maker.
BelgiumRIVIZ2018
CroatiaAAZ2017-A summary of the report was prepared in the national language, as well as assessment elements B0001 and A0020, with links to the full report on English language. Upon Croatian decision makers request on this topic, the report will be updated if needed and local information will be added (i.e., epidemiological information such as patient numbers; the technologies available in Croatia, information about costs…), including recommendations.
Czech RepublicSUKLOngoingNational adaptation. Added local information. Translation of key summaries into national language.
FranceHASOn-going-Cited in the national report as background or additional information.
SpainAETSA2018http://www.aetsa.org/publicacion/midostaurina-asociada-a-quimioterapia-estandar-en-leucemia-mieloide-aguda-con-mutacion-flt3/ A summary of this EUnetHTA assessment in Spanish together with the full English report has been published on AETSA's website for dissemination. In addition, the report has been distributed to the regional decision-maker and haematologists
ItalyAIFA2017-Used for background information
PortugalINFARMED2018National adaptation: Use of the EUnetHTA assessment to support the production of the national report, including citation in the national report, use of the EUnetHTA literature searches, minor changes to the content in the EUnetHTA assessment and addition of local information.
SlovakiaUNIBA2018National Adaptation. Added local information.
SpainAEMPS2017-Cited in the national report as background or additional information.
SwedenTLV2018National adaptation. Cited in the national report as background or additional information. Added local information and cost effectiveness analysis.
UK (Scotland)HIS2017https://www.scottishmedicines.org.uk/media/3471/midostaurin-rydapt-final-may-2018-for-website.pdUsed for validation of submission from the technology developer
UKNICE2017https://www.evidence.nhs.uk/Search?q=EUnetHTAEUnetHTA reports are indexed in NHS Evidence, a public database which provides access to selected sources of evidence in health, social case and public health.